Headquartered in New York, Snow Phipps has overseen the deployment of over $1.7 billion of private equity capital and co-investments in 17 platform investments and over 25 add-on acquisitions since inception.
Modern Healthcare is reporting on the recently handed down Supreme Court decision in Cuozzo Speed Technologies v. Lee, which might make it easier for generic drug makers to manufacture generics, but could also make it difficult for companies to protect their patents. The decision allows the Patent and Trademark Office's board for patent trial and appeal to use a broad standard when interpreting patent claims. The Generic Pharmaceutical Association Monday called the decision "one that promotes a competitive, affordable prescription drug market for consumers." (Modern Healthcare)
The pilot program, which in effect would allow the DoD to access lower pricing for prescriptions dispensed at community pharmacies, is included in the version of the NDAA passed by the House on May 18, but not in the version passed by the Senate June 14.
Mylan on Thursday launched two new generic products. The company rolled out its generic of Celgene’s Vidaza (azacitidine, 100 mg/vial) injection and its generic of GSK’s Rhythmol (propafenone HCl) extended-release capsules.
The Economic Times is reporting that drugmaker Sun Pharma recently received a subpoena from the Department of Justice looking for information about its U.S. subsidiary’s practices in selling and marketing the company’s generics. The report noted that this is the latest move in a larger regulatory interest in generic drug prices in the last year. (Economic Times)
CVS Health’s efforts to dispense opioid overdose reversal drug naloxone without a prescription has already come to 23 states and the company has announced plans to expand to seven more over the course of the summer.